Used in the treatment of Parkinson’s disease, this compound enhances the effectiveness of levodopa therapy by inhibiting the COMT enzyme, which breaks down levodopa in the bloodstream. By blocking this breakdown, it allows more levodopa to reach the brain, leading to improved motor control and more consistent symptom relief. It is typically administered alongside levodopa and carbidopa in patients experiencing motor fluctuations. This agent helps reduce "off" periods, where movement is difficult, and extends the duration of levodopa’s effect, improving daily function and quality of life in advanced Parkinson’s cases.